1,089 results on '"Berkhout, Ben"'
Search Results
2. Persistent HIV-1 transcription during ART: time to reassess its significance?
3. Novel role of UHRF1 in the epigenetic repression of the latent HIV-1
4. In-house ELISA protocols for capsid p24 detection of diverse HIV isolates
5. HIV co-opts a cellular antiviral mechanism, activation of stress kinase PKR by its RNA, to enable splicing of rev/tat mRNA
6. AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery
7. CRISPR-Cas12b enables a highly efficient attack on HIV proviral DNA in T cell cultures
8. ‘Zombie’ proviruses in the spotlight: exploring the dark side of HIV persistence
9. FcγRIIA-specific DARPins as novel tools in blood cell analysis and platelet aggregation
10. HIV persistence: silence or resistance?
11. Towards a molecular profile of antiretroviral therapy-free HIV remission
12. Viruses in the reproductive tract: On their way to the germ line?
13. Human Immunodeficiency Virus Resistance to Dolutegravir : Are We Looking in the Wrong Place?
14. Integration of SARS-CoV-2 RNA in infected human cells by retrotransposons: an unlikely hypothesis and old viral relationships
15. Elimination of infectious HIV DNA by CRISPR–Cas9
16. Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines
17. Influence of a 3′ Terminal Ribozyme on AgoshRNA Biogenesis and Activity
18. DC-SIGN Polymorphisms Associate with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users
19. Assessing proviral competence: current approaches to evaluate HIV-1 persistence
20. The evolution of subtype B HIV-1 tat in the Netherlands during 1985–2012
21. CRISPR-Cas based antiviral strategies against HIV-1
22. Human Coronavirus NL63 Employs the Severe Acute Respiratory Syndrome Coronavirus Receptor for Cellular Entry
23. From clinical sample to complete genome: Comparing methods for the extraction of HIV-1 RNA for high-throughput deep sequencing
24. In vitro Evolution of a Highly Replicating, Doxycycline-Dependent HIV for Applications in Vaccine Studies
25. Conditionally replicating HIV and SIV variants
26. A trip down memory lane with Retrovirology
27. On the generation of the MSD-Ѱ class of defective HIV proviruses
28. Recent Advances Using Genetic Therapies Against Infectious Diseases and for Vaccination.
29. On the biased nucleotide composition of the human coronavirus RNA genome
30. On the nucleotide composition and structure of retroviral RNA genomes
31. The search for a T cell line for testing novel antiviral strategies against HIV-1 isolates of diverse receptor tropism and subtype origin
32. Antiviral strategies combining antiretroviral drugs with RNAi-mediated attack on HIV-1 and cellular co-factors
33. Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity
34. Modest Nonadherence to Antiretroviral Therapy Promotes Residual HIV-1 Replication in the Absence of Virological Rebound in Plasma
35. Selective packaging of cellular miRNAs in HIV-1 particles
36. Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2.
37. Correction: HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry
38. Design of modified U1i molecules against HIV-1 RNA
39. Efficient CRM197-mediated drug targeting to monocytes
40. HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms
41. Molecular strategies to design an escape-proof antiviral therapy
42. Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors
43. Rise in seroprevalence of herpes simplex virus type 1 among highly sexual active homosexual men and an increasing association between herpes simplex virus type 2 and HIV over time (1984–2003)
44. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users
45. Lack of Association between Infection with a Novel Human Coronavirus (HCoV), HCoV-NH, and Kawasaki Disease in Taiwan
46. Questions Concerning the New Haven Coronavirus
47. A CRISPR-Cas Cure for HIV/AIDS.
48. Optimization of shRNA inhibitors by variation of the terminal loop sequence
49. REPLICATION KINETICS AND PERSISTENCE OF A CONDITIONALLY LIVE ATTENUATED SIV (SIVRTTA) IN VIVO CONFERS PROTECTION AGAINST HOMOLOGOUS AND HETEROLOGOUS SIV CHALLENGE: O6.07
50. Association between gp120 envelope V1V2 and V4V5 variable loop profiles in a defined HIV-1 transmission cluster
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.